Corvus Pharmaceuticals Inc. hopes to catch the next wave of the immuno-oncology revolution by developing drugs that can treat patients who are resistant/refractory to PD-1/L1 inhibitors, by blocking the effects of the signaling molecule adenosine.
It's impossible to overestimate the impact that checkpoint inhibitors have had in cancer treatment. In some tumor types, however, response...








